Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert*, Monika E. Hegi, Martin J. van den Bent, Andreas von Deimling, Thierry Gorlia, Khê Hoang-Xuan, Alba A. Brandes, Guy Kantor, Martin J.B. Taphoorn, Mohamed Ben Hassel, Christian Hartmann, Gail Ryan, David Capper, Johan M. Kros, Sebastian Kurscheid, Wolfgang Wick, Roelien Enting, Michele Reni, Brian Thiessen, Frederic DhermainJacoline E. Bromberg, Loic Feuvret, Jaap C. Reijneveld, Olivier Chinot, Johanna M.M. Gijtenbeek, John P. Rossiter, Nicolas Dif, Carmen Balana, Jose Bravo-Marques, Paul M. Clement, Christine Marosi, Tzahala Tzuk-Shina, Robert A. Nordal, Jeremy Rees, Denis Lacombe, Warren P. Mason, Roger Stupp

*Corresponding author for this work

    Research output: Contribution to journal › Article › peer-review

    397 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study'. Together they form a unique fingerprint.

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science

    Neuroscience